Lung cancer, the leading cause of cancer mortality, exhibits heterogeneity that enables
adaptability, limits therapeutic success, and remains incompletely understood. Single-cell …

Advanced metastatic cancer poses utmost clinical challenges and may present molecular
and cellular features distinct from an early-stage cancer. Herein, we present single-cell …

Background Intra-tumoral genetic and functional heterogeneity correlates with cancer
clinical prognoses. However, the mechanisms by which intra-tumoral heterogeneity impacts …

Background Lung cancer, one of the most common malignant tumors, exhibits high inter-and
intra-tumor heterogeneity which contributes significantly to treatment resistance and failure …

Background Precision therapy for lung cancer will require comprehensive genomic testing to
identify actionable targets as well as ascertain disease prognosis. RNA-seq is a robust …

Lung cancer is a highly heterogeneous disease. Cancer cells and cells within the tumor
microenvironment together determine disease progression, as well as response to or …

Lung adenocarcinoma (LUAD) and squamous carcinoma (LUSC) are two major subtypes of
non-small cell lung cancer with distinct pathologic features and treatment paradigms. The …

As single-cell RNA sequencing (scRNA-seq) has emerged as a great tool for studying
cellular heterogeneity within the past decade, the number of available scRNA-seq datasets …

The biggest hurdle to targeted cancer therapy is the inevitable emergence of drug
resistance. Tumor cells employ different mechanisms to resist the targeting agent. Most …

Identifying molecular residual disease (MRD) after treatment of localized lung cancer could
facilitate early intervention and personalization of adjuvant therapies. Here, we apply cancer …